Notably, we demonstrated that the selected aptamer HMAP7 exhibited the highest potential to discriminate between HER2-positive and -negative breast cancer cells, suggesting its potential for specific targeting of HER2-overexpressing cancer cells. Here, ERBB2 is linked to cancer.